Crescita Therpeutc (TSE:CTX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Crescita Therapeutics Inc. has enhanced its market position by completing the acquisition of Occy Laboratory’s business assets, which includes manufacturing equipment, inventory, and intellectual property. The deal, valued at $0.9 million, is expected to be accretive to Crescita’s EBITDA following integration. Occy, facing bankruptcy proceedings, was approved for asset sale by the Québec Superior Court, and Crescita will maintain Occy’s commercial operations.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.